Valeant Makes Its First Acquisition Move Of The Year, In Dermatology
This article was originally published in The Pink Sheet Daily
Executive Summary
Valeant Pharmaceuticals will continue its march into dermatology with the acquisition of PreCision Dermatology for $475 million in cash plus milestones. The deal represents a bolt-on opportunity for Valeant, which will leverage its existing infrastructure to sell PreCision’s products.